NightHawk Biosciences, Inc.(NYSE Amex Equities : NHWK)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.85%||180.99||0.7%||$1263.76m|
|BMY||Bristol-Myers Squibb Co.||-1.86%||76.15||1.0%||$1200.63m|
|MRK||Merck & Co., Inc.||0.77%||93.02||0.7%||$1171.65m|
|LLY||Eli Lilly & Co.||3.15%||323.34||1.1%||$1017.85m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.15%||143.40||0.0%||$499.78m|
|SIGA||SIGA Technologies, Inc.||41.91%||13.68||0.0%||$209.92m|
|HZNP||Horizon Therapeutics Plc||4.69%||94.84||5.4%||$209.26m|
|NVO||Novo Nordisk A/S||1.07%||107.74||0.1%||$184.03m|
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.